title: Molecular imaging to target transplanted muscle progenitor cells.
abstract: Duchenne muscular dystrophy (DMD) is a severe genetic neuromuscular disorder that affects 1 in 3,500 boys, and is characterized by progressive muscle degeneration. In patients, the ability of resident muscle satellite cells (SCs) to regenerate damaged myofibers becomes increasingly inefficient. Therefore, transplantation of muscle progenitor cells (MPCs)/myoblasts from healthy subjects is a promising therapeutic approach to DMD. A major limitation to the use of stem cell therapy, however, is a lack of reliable imaging technologies for long-term monitoring of implanted cells, and for evaluating its effectiveness. Here, we describe a non-invasive, real-time approach to evaluate the success of myoblast transplantation. This method takes advantage of a unified fusion reporter gene composed of genes (firefly luciferase [fluc], monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk]) whose expression can be imaged with different imaging modalities. A variety of imaging modalities, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical imaging, and high frequency 3D-ultrasound are now available, each with unique advantages and limitations. Bioluminescence imaging (BLI) studies, for example, have the advantage of being relatively low cost and high-throughput. It is for this reason that, in this study, we make use of the firefly luciferase (fluc) reporter gene sequence contained within the fusion gene and bioluminescence imaging (BLI) for the short-term localization of viable C2C12 myoblasts following implantation into a mouse model of DMD (muscular dystrophy on the X chromosome [mdx] mouse). Importantly, BLI provides us with a means to examine the kinetics of labeled MPCs post-implantation, and will be useful to track cells repeatedly over time and following migration. Our reporter gene approach further allows us to merge multiple imaging modalities in a single living subject; given the tomographic nature, fine spatial resolution and ability to scale up to larger animals and humans, PET will form the basis of future work that we suggest may facilitate rapid translation of methods developed in cells to preclinical models and to clinical applications.
authors.affiliation: Imaging Program, Lawson Health Research Institute, USA.
authors.forename: Kelly
authors.initials: K
authors.lastname: Gutpell
authors.forename: Rebecca
authors.initials: R
authors.lastname: McGirr
authors.forename: Lisa
authors.initials: L
authors.lastname: Hoffman
mesh_terms: D000818:Animals; D017930:Genes, Reporter; D008163:Luminescent Measurements / Q000379:methods*; D051379:Mice; D057054:Molecular Imaging / Q000379:methods*; D009137:Muscular Dystrophy, Animal / Q000601:surgery; D020388:Muscular Dystrophy, Duchenne / Q000601:surgery; D032446:Myoblasts / Q000166:cytology* / Q000637:transplantation*; D049268:Positron-Emission Tomography; D033581:Stem Cell Transplantation / Q000379:methods*; D014162:Transfection